| 前收盘价格 | 177.58 |
| 收盘价格 | 178.35 |
| 成交量 | 299,109 |
| 平均成交量 (3个月) | 227,543 |
| 市值 | 6,297,956,352 |
| 预期市盈率 (P/E Forward) | 227.27 |
| 股市价格/股市净资产 (P/B) | 24.31 |
| 52周波幅 | |
| 利润日期 | 12 May 2026 |
| 稀释每股收益 (EPS TTM) | -1.36 |
| 总债务/股东权益 (D/E MRQ) | 0.37% |
| 流动比率 (MRQ) | 25.98 |
| 营业现金流 (OCF TTM) | -29.23 M |
| 杠杆自由现金流 (LFCF TTM) | -13.42 M |
| 资产报酬率 (ROA TTM) | -22.23% |
| 股东权益报酬率 (ROE TTM) | -33.43% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Belite Bio, Inc | 看涨 | 看涨 |
AIStockmoo 评分
0.1
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -5.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.13 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 53.93% |
| 机构持股比例 | 0.75% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Darwin Global Management, Ltd. | 31 Dec 2025 | 3,027,704 |
| Ra Capital Management, L.P. | 31 Dec 2025 | 432,484 |
| Perceptive Advisors Llc | 31 Dec 2025 | 414,239 |
| Eventide Asset Management, Llc | 31 Dec 2025 | 383,091 |
| Deerfield Management Company, L.P. | 31 Dec 2025 | 233,813 |
| Mpm Bioimpact Llc | 31 Dec 2025 | 87,760 |
| Holocene Advisors, Lp | 31 Dec 2025 | 84,067 |
| Fred Alger Management, Llc | 31 Dec 2025 | 79,394 |
| Western Standard Llc | 31 Dec 2025 | 60,026 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 266.00 (Cantor Fitzgerald, 58.45%) | 购买 |
| 中 | 200.50 (19.43%) | |
| 低 | 195.00 (B of A Securities, 16.15%) | 购买 |
| 平均值 | 215.50 (28.37%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 166.53 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 03 Mar 2026 | 266.00 (58.45%) | 购买 | 167.88 |
| HC Wainwright & Co. | 03 Mar 2026 | 200.00 (19.13%) | 购买 | 167.88 |
| 28 Jan 2026 | 185.00 (10.20%) | 购买 | 165.64 | |
| Morgan Stanley | 03 Mar 2026 | 201.00 (19.73%) | 购买 | 167.88 |
| 06 Jan 2026 | 191.00 (13.77%) | 购买 | 160.18 | |
| B of A Securities | 26 Jan 2026 | 195.00 (16.15%) | 购买 | 162.47 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合